Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis
Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance th...
Saved in:
Published in | Arthritis research & therapy Vol. 11; no. 5; p. R149 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
01.01.2009
BioMed Central Ltd National Library of Medicine - MEDLINE Abstracts |
Subjects | |
Online Access | Get full text |
ISSN | 1478-6354 1478-6362 1478-6354 1478-6362 |
DOI | 10.1186/ar2823 |
Cover
Abstract | Introduction
Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation.
Methods
Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by
3
H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay.
Results
Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27
+
than CD27
-
peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27
+
B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor.
Conclusions
The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium. |
---|---|
AbstractList | INTRODUCTION: Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation. METHODS: Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay. RESULTS: Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27+ than CD27- peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27+ B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor. CONCLUSIONS: The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium. Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation. Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay. Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27+ than CD27- peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27+ B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor. The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium. Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation. Methods Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by .sup.3.sup.H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay. Results Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27.sup.+ .sup.than CD27.sup.- .sup.peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27.sup.+ .sup.B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor. Conclusions The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium. Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation. Methods Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3 H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay. Results Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27 + than CD27 - peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27 + B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor. Conclusions The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium. Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation.INTRODUCTIONAccumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation.Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay.METHODSCell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay.Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27+ than CD27- peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27+ B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor.RESULTSSignificant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27+ than CD27- peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27+ B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor.The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium.CONCLUSIONSThe data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium. |
ArticleNumber | R149 |
Audience | Academic |
Author | Lipsky, Peter E Kanegane, Hirokazu Komano, Yukiko Nanki, Toshihiro Miyasaka, Nobuyuki Takada, Kazuki Morio, Tomohiro Nakajima, Atsuo |
AuthorAffiliation | 1 Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan 3 Department of Pediatrics and Developmental Biology, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan 2 Department of Pharmacovigilance, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan 5 Department of Joint Disease and Rheumatism, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan 4 Department of Pediatrics, Graduate School of Medicine, University of Toyama, 2630, Sugitani, Toyama, 930-0194, Japan 8 Global Center of Excellence (GCOE) Program; International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan 7 National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 90 |
AuthorAffiliation_xml | – name: 6 Department of Rheumatology, Tokyo Metropolitan Police Hospital, 4-22-1, Nakano, Nakano-ku, Tokyo, 164-8541, Japan – name: 8 Global Center of Excellence (GCOE) Program; International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan – name: 3 Department of Pediatrics and Developmental Biology, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan – name: 5 Department of Joint Disease and Rheumatism, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan – name: 7 National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA – name: 1 Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan – name: 2 Department of Pharmacovigilance, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan – name: 4 Department of Pediatrics, Graduate School of Medicine, University of Toyama, 2630, Sugitani, Toyama, 930-0194, Japan |
Author_xml | – sequence: 1 givenname: Toshihiro surname: Nanki fullname: Nanki, Toshihiro email: nanki.rheu@tmd.ac.jp organization: Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, Department of Pharmacovigilance, Graduate School, Tokyo Medical and Dental University – sequence: 2 givenname: Kazuki surname: Takada fullname: Takada, Kazuki organization: Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University – sequence: 3 givenname: Yukiko surname: Komano fullname: Komano, Yukiko organization: Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, Department of Pharmacovigilance, Graduate School, Tokyo Medical and Dental University – sequence: 4 givenname: Tomohiro surname: Morio fullname: Morio, Tomohiro organization: Department of Pediatrics and Developmental Biology, Graduate School, Tokyo Medical and Dental University – sequence: 5 givenname: Hirokazu surname: Kanegane fullname: Kanegane, Hirokazu organization: Department of Pediatrics, Graduate School of Medicine, University of Toyama – sequence: 6 givenname: Atsuo surname: Nakajima fullname: Nakajima, Atsuo organization: Department of Joint Disease and Rheumatism, Nippon Medical School, Department of Rheumatology, Tokyo Metropolitan Police Hospital – sequence: 7 givenname: Peter E surname: Lipsky fullname: Lipsky, Peter E organization: National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health – sequence: 8 givenname: Nobuyuki surname: Miyasaka fullname: Miyasaka, Nobuyuki organization: Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, Global Center of Excellence (GCOE) Program; International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19804625$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kktv1DAQxyNURB_AR0AWB7iwxa_YDgeksuIlVeIC58hxJhuXxA62g-AL8Llxulu2XQTywR7Pb_6eGc9pceS8g6J4TPA5IUq81IEqyu4VJ4RLtRKs5Ee3zsfFaYxXGFNaUf6gOCaVwlzQ8qT4te5h9F-tAxTAwJR8QPBjChCj9Q5p16JudiZlQw8Iug5Mish3yNzEZcuhN8jAMMRXyI7TYI1eeGQdSj2gSafebyCT9joy9DCPOnnbIh1SH2yy8WFxv9NDhEe7_az48u7t5_WH1eWn9x_XF5erRhCcVkxwooDTSpGyrHhjpGC4aXWFQVRKY0Y4aM4kmKpTmpPGGAxSCEw16zST7Kx4vdWd5maE1oBLQQ_1FOyow8_aa1vf9Tjb1xv_vaZSSapEFqi2Ao31_xC46zF-rLefk2Of7x4P_tsMMdWjjUvftAM_x1oyTkpZCprJZ_8lKaGSCbyk8_QAvPJzyF-1MJKrSlKeofMttNED1NZ1Pmdm8mphtCbPUWfz_QUlGJeSi0X1ye0u_anuZmz2-ZngYwzQ7RFcL_O4L_nFAWhsup6OnIId_sZ3HYpZz20g7Ms5IH8DtkPxlg |
CitedBy_id | crossref_primary_10_1016_j_cellimm_2020_104263 crossref_primary_10_1038_icb_2010_158 crossref_primary_10_1016_j_jdsr_2019_09_006 crossref_primary_10_3109_13880209_2015_1074254 crossref_primary_10_1080_14397595_2017_1341458 crossref_primary_10_1016_j_rdc_2010_02_003 crossref_primary_10_1111_eci_12063 crossref_primary_10_1002_advs_202409537 crossref_primary_10_1002_art_38137 crossref_primary_10_4049_jimmunol_1001139 crossref_primary_10_1593_tlo_11115 crossref_primary_10_1111_ajt_13207 crossref_primary_10_1111_aji_13154 crossref_primary_10_1039_c2cs35085h crossref_primary_10_3389_fimmu_2018_01707 crossref_primary_10_1016_j_heliyon_2024_e27861 crossref_primary_10_1016_j_imlet_2018_05_003 crossref_primary_10_1080_14397595_2016_1213481 crossref_primary_10_1002_advs_202308447 crossref_primary_10_1186_s43042_024_00550_1 crossref_primary_10_1038_emm_2017_100 crossref_primary_10_1038_s41598_020_71362_7 crossref_primary_10_1016_j_sjbs_2020_08_045 crossref_primary_10_1038_s41598_017_09150_z crossref_primary_10_1111_cei_12065 crossref_primary_10_1016_j_jaut_2020_102526 crossref_primary_10_1038_s41408_018_0130_3 crossref_primary_10_1002_art_38023 crossref_primary_10_1016_j_dci_2014_07_008 crossref_primary_10_1155_2012_391567 crossref_primary_10_1093_rheumatology_kez175 crossref_primary_10_3109_03009742_2013_803149 crossref_primary_10_3389_fimmu_2023_1100869 crossref_primary_10_1038_s41584_019_0323_6 crossref_primary_10_1016_j_mcpro_2022_100258 crossref_primary_10_18632_oncotarget_8163 crossref_primary_10_3390_ijms20215287 crossref_primary_10_1016_j_imlet_2020_06_014 crossref_primary_10_1080_13880209_2022_2143533 crossref_primary_10_1126_scitranslmed_3005407 crossref_primary_10_2177_jsci_39_172 crossref_primary_10_3390_vaccines9101171 crossref_primary_10_1016_j_cyto_2013_05_020 crossref_primary_10_3899_jrheum_110049 crossref_primary_10_1111_imm_13840 crossref_primary_10_1186_ar3158 crossref_primary_10_2310_7290_2014_00041 crossref_primary_10_1007_s12016_015_8520_9 crossref_primary_10_1016_j_mehy_2024_111422 crossref_primary_10_1186_s13075_018_1611_2 crossref_primary_10_1007_s00018_023_04715_w crossref_primary_10_3389_fimmu_2020_01913 crossref_primary_10_1111_j_1600_0897_2012_01167_x crossref_primary_10_1038_icb_2013_97 crossref_primary_10_1155_2014_681678 crossref_primary_10_1007_s10067_017_3652_3 crossref_primary_10_1186_s13075_015_0561_1 crossref_primary_10_3389_fcell_2022_882017 crossref_primary_10_3389_fimmu_2018_01924 crossref_primary_10_1186_s13075_016_0978_1 crossref_primary_10_1089_dna_2011_1350 crossref_primary_10_1371_journal_pone_0058140 crossref_primary_10_1002_art_27650 crossref_primary_10_1016_j_clinthera_2018_04_016 crossref_primary_10_1161_ATVBAHA_124_321434 crossref_primary_10_1016_j_cellsig_2019_109395 crossref_primary_10_1186_s13075_016_0957_6 crossref_primary_10_1189_jlb_1010565 crossref_primary_10_1124_pr_113_007724 crossref_primary_10_2174_1570163816666191023103118 crossref_primary_10_1016_j_autrev_2011_06_010 crossref_primary_10_1016_j_bbamcr_2014_05_014 crossref_primary_10_2174_1381612827666211104154459 crossref_primary_10_1016_j_it_2014_12_006 crossref_primary_10_1142_S0218339013500174 crossref_primary_10_1016_j_intimp_2023_110530 crossref_primary_10_1155_2022_7719301 crossref_primary_10_3389_fcimb_2019_00280 crossref_primary_10_1038_nrrheum_2010_68 crossref_primary_10_3390_pathophysiology31030038 crossref_primary_10_1016_j_yexcr_2010_12_017 crossref_primary_10_1016_j_jid_2019_07_717 crossref_primary_10_1186_s13075_016_1102_2 crossref_primary_10_1002_art_27767 crossref_primary_10_1016_j_jaut_2021_102684 crossref_primary_10_3389_fimmu_2022_907733 crossref_primary_10_1371_journal_pone_0101622 crossref_primary_10_3389_fimmu_2023_1331796 crossref_primary_10_3390_molecules24193591 crossref_primary_10_1182_blood_2016_08_735076 crossref_primary_10_1186_s13075_016_1065_3 |
Cites_doi | 10.1038/sj.leu.2402107 10.1136/ard.51.9.1029 10.1002/art.1780350809 10.4049/jimmunol.165.11.6590 10.1038/16717 10.1002/art.21301 10.1006/cimm.2001.1890 10.1111/j.1365-2249.1995.tb03126.x 10.1002/art.22025 10.1016/S1074-7613(00)80165-X 10.1186/ar2107 10.4049/jimmunol.167.9.5381 10.1186/ar77 10.1016/S0065-2776(01)78002-9 10.1111/j.1365-2249.1994.tb06109.x 10.4049/jimmunol.168.10.5333 10.4049/jimmunol.148.10.3296 10.1016/j.cyto.2008.06.017 10.1186/ar2333 10.1007/s00296-004-0449-x 10.1186/ar2125 10.4049/jimmunol.170.12.6320 10.4049/jimmunol.166.1.650 10.1093/rheumatology/40.2.205 10.1097/01.LAB.0000062854.30195.52 10.1002/art.20932 10.1186/ar2718 10.1186/ar2200 10.1056/NEJM200011303432202 10.4049/jimmunol.172.6.3422 10.1182/blood.V95.2.627 10.1002/art.1780310302 10.1093/intimm/12.9.1285 10.4049/jimmunol.164.10.5010 10.4049/jimmunol.165.6.3423 10.1073/pnas.93.1.221 10.1016/j.berh.2006.06.001 10.1084/jem.173.2.487 |
ContentType | Journal Article |
Copyright | Nanki et al.; licensee BioMed Central Ltd. 2009 COPYRIGHT 2009 BioMed Central Ltd. Copyright National Library of Medicine - MEDLINE Abstracts 2009 Copyright ©2009 Nanki et al.; licensee BioMed Central Ltd. 2009 Nanki et al.; licensee BioMed Central Ltd. |
Copyright_xml | – notice: Nanki et al.; licensee BioMed Central Ltd. 2009 – notice: COPYRIGHT 2009 BioMed Central Ltd. – notice: Copyright National Library of Medicine - MEDLINE Abstracts 2009 – notice: Copyright ©2009 Nanki et al.; licensee BioMed Central Ltd. 2009 Nanki et al.; licensee BioMed Central Ltd. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7QP 7T5 H94 7X8 5PM |
DOI | 10.1186/ar2823 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Calcium & Calcified Tissue Abstracts Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) AIDS and Cancer Research Abstracts Calcium & Calcified Tissue Abstracts Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1478-6354 1478-6362 |
EndPage | R149 |
ExternalDocumentID | PMC2787286 oai_biomedcentral_com_ar2823 1916818401 A210057466 19804625 10_1186_ar2823 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GroupedDBID | --- .GJ 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 AAFWJ AAJSJ AASML ACGFS ACJQM ADBBV ADUKV AEGXH AENEX AFPKN AHBYD AHMBA AHSBF ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C1A C6C CS3 DIK E3Z EBLON EJD F5P GROUPED_DOAJ GX1 H13 HYE HZ~ INH INR ITC KQ8 O5R O5S O9- PGMZT PIMPY PQQKQ RBZ ROL RPM RSV SMD SOJ TR2 U2A WOQ AAYXX ALIPV CITATION 7X7 88E 8FI 8FJ ABUWG AFKRA AHYZX BPHCQ BVXVI CCPQU CGR CUY CVF EBD ECM EIF EMOBN FYUFA HMCUK M1P NPM PHGZT PROAC PSQYO SV3 UKHRP ZGI K9. 7QP 7T5 H94 7X8 -5E -5G -A0 -BR 3V. ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 IAO IHR Z7U ZA5 5PM |
ID | FETCH-LOGICAL-b610t-36418e429815594bc7630bda90e698a0314ea437ec9f8a41bcc0e76602a3fa373 |
IEDL.DBID | U2A |
ISSN | 1478-6354 1478-6362 |
IngestDate | Thu Aug 21 14:05:41 EDT 2025 Wed May 22 07:11:13 EDT 2024 Thu Sep 04 23:56:40 EDT 2025 Thu Sep 04 15:53:09 EDT 2025 Mon Jun 30 16:54:52 EDT 2025 Tue Jun 10 21:24:42 EDT 2025 Thu Apr 03 07:09:50 EDT 2025 Tue Jul 01 04:00:29 EDT 2025 Thu Apr 24 22:58:33 EDT 2025 Sat Sep 06 07:28:13 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Rheumatoid Arthritis Peripheral Blood CD27 Tumor Necrosis Factor Production Synovial Tissue Rheumatoid Arthritis Synovium |
Language | English |
License | This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b610t-36418e429815594bc7630bda90e698a0314ea437ec9f8a41bcc0e76602a3fa373 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://link.springer.com/10.1186/ar2823 |
PMID | 19804625 |
PQID | 217489724 |
PQPubID | 42875 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2787286 biomedcentral_primary_oai_biomedcentral_com_ar2823 proquest_miscellaneous_734157562 proquest_miscellaneous_21273606 proquest_journals_217489724 gale_infotracacademiconefile_A210057466 pubmed_primary_19804625 crossref_primary_10_1186_ar2823 crossref_citationtrail_10_1186_ar2823 springer_journals_10_1186_ar2823 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2009-01-01 |
PublicationDateYYYYMMDD | 2009-01-01 |
PublicationDate_xml | – month: 01 year: 2009 text: 2009-01-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Arthritis research & therapy |
PublicationTitleAbbrev | Arthritis Res Ther |
PublicationTitleAlternate | Arthritis Res Ther |
PublicationYear | 2009 |
Publisher | BioMed Central BioMed Central Ltd National Library of Medicine - MEDLINE Abstracts |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: National Library of Medicine - MEDLINE Abstracts |
References | O Yoshie (2660_CR12) 2001; 78 MP Armengol (2660_CR18) 2003; 170 T Nanki (2660_CR38) 2001; 167 C Mauri (2660_CR6) 2007; 9 ME Duddy (2660_CR10) 2004; 172 T Jin (2660_CR13) 2008; 44 T Nanki (2660_CR36) 2000; 164 A Zlotnik (2660_CR11) 2000; 12 T Nanki (2660_CR35) 2005; 52 A Hutloff (2660_CR34) 1999; 397 SK Lundy (2660_CR3) 2007; 9 HJ Kim (2660_CR30) 2000; 2 D Jones (2660_CR19) 2000; 95 SK Lee (2660_CR31) 1992; 35 PE Lipsky (2660_CR33) 2000; 343 T Nanki (2660_CR28) 2000; 165 S Hosaka (2660_CR22) 1994; 97 K Shi (2660_CR29) 2001; 166 RW Kinne (2660_CR4) 2007; 9 SB Cohen (2660_CR2) 2006; 54 D van Zeben (2660_CR9) 1992; 51 G Page (2660_CR25) 2002; 168 E Robinson (2660_CR23) 1995; 101 A Ueno (2660_CR26) 2005; 25 FC Arnett (2660_CR16) 1988; 31 JH Ruth (2660_CR24) 2003; 83 V Lutzky (2660_CR5) 2007; 9 I Randen (2660_CR7) 1992; 148 PP Tak (2660_CR15) 2006; 20 AE Schroder (2660_CR32) 1996; 93 E Roosnek (2660_CR8) 1991; 173 AE Koch (2660_CR14) 2005; 52 CD Buckley (2660_CR27) 2000; 165 J Durig (2660_CR20) 2001; 15 MM Souto-Carneiro (2660_CR21) 2009; 11 T Nanki (2660_CR37) 2001; 214 M Brandes (2660_CR17) 2000; 12 JC Edwards (2660_CR1) 2001; 40 15004141 - J Immunol. 2004 Mar 15;172(6):3422-7 10799853 - J Immunol. 2000 May 15;164(10):5010-4 3358796 - Arthritis Rheum. 1988 Mar;31(3):315-24 10627472 - Blood. 2000 Jan 15;95(2):627-32 12794165 - J Immunol. 2003 Jun 15;170(12):6320-8 16980215 - Best Pract Res Clin Rheumatol. 2006 Oct;20(5):929-39 10714678 - Immunity. 2000 Feb;12(2):121-7 17850683 - Arthritis Res Ther. 2007;9(4):219 12695561 - Lab Invest. 2003 Apr;83(4):579-88 16947627 - Arthritis Rheum. 2006 Sep;54(9):2793-806 9930702 - Nature. 1999 Jan 21;397(6716):263-6 15004722 - Rheumatol Int. 2005 Jun;25(5):361-7 11086103 - J Immunol. 2000 Dec 1;165(11):6590-8 1578151 - J Immunol. 1992 May 15;148(10):3296-301 11096166 - N Engl J Med. 2000 Nov 30;343(22):1594-602 1703209 - J Exp Med. 1991 Feb 1;173(2):487-9 17349064 - Arthritis Res Ther. 2007;9(2):205 11994492 - J Immunol. 2002 May 15;168(10):5333-41 7545093 - Clin Exp Immunol. 1995 Sep;101(3):398-407 16200580 - Arthritis Rheum. 2005 Oct;52(10):3004-14 7521808 - Clin Exp Immunol. 1994 Sep;97(3):451-7 11094422 - Arthritis Res. 2000;2(2):126-31 12088413 - Cell Immunol. 2001 Dec 15;214(2):145-54 1642656 - Arthritis Rheum. 1992 Aug;35(8):905-13 11123349 - J Immunol. 2001 Jan 1;166(1):650-5 11432208 - Adv Immunol. 2001;78:57-110 15751074 - Arthritis Rheum. 2005 Mar;52(3):710-21 11673556 - J Immunol. 2001 Nov 1;167(9):5381-5 11368435 - Leukemia. 2001 May;15(5):752-6 1417131 - Ann Rheum Dis. 1992 Sep;51(9):1029-35 19500335 - Arthritis Res Ther. 2009;11(3):R84 11257159 - Rheumatology (Oxford). 2001 Feb;40(2):205-11 18177511 - Arthritis Res Ther. 2007;9(6):224 10975862 - J Immunol. 2000 Sep 15;165(6):3423-9 17306038 - Arthritis Res Ther. 2007;9(1):202 8552609 - Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):221-5 18722135 - Cytokine. 2008 Oct;44(1):1-8 10967023 - Int Immunol. 2000 Sep;12(9):1285-92 |
References_xml | – volume: 15 start-page: 752 year: 2001 ident: 2660_CR20 publication-title: Leukemia doi: 10.1038/sj.leu.2402107 – volume: 51 start-page: 1029 year: 1992 ident: 2660_CR9 publication-title: Ann Rheum Dis doi: 10.1136/ard.51.9.1029 – volume: 35 start-page: 905 year: 1992 ident: 2660_CR31 publication-title: Arthritis Rheum doi: 10.1002/art.1780350809 – volume: 165 start-page: 6590 year: 2000 ident: 2660_CR28 publication-title: J Immunol doi: 10.4049/jimmunol.165.11.6590 – volume: 397 start-page: 263 year: 1999 ident: 2660_CR34 publication-title: Nature doi: 10.1038/16717 – volume: 52 start-page: 3004 year: 2005 ident: 2660_CR35 publication-title: Arthritis Rheum doi: 10.1002/art.21301 – volume: 214 start-page: 145 year: 2001 ident: 2660_CR37 publication-title: Cell Immunol doi: 10.1006/cimm.2001.1890 – volume: 101 start-page: 398 year: 1995 ident: 2660_CR23 publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.1995.tb03126.x – volume: 54 start-page: 2793 year: 2006 ident: 2660_CR2 publication-title: Arthritis Rheum doi: 10.1002/art.22025 – volume: 12 start-page: 121 year: 2000 ident: 2660_CR11 publication-title: Immunity doi: 10.1016/S1074-7613(00)80165-X – volume: 9 start-page: 202 year: 2007 ident: 2660_CR3 publication-title: Arthritis Res Ther doi: 10.1186/ar2107 – volume: 167 start-page: 5381 year: 2001 ident: 2660_CR38 publication-title: J Immunol doi: 10.4049/jimmunol.167.9.5381 – volume: 2 start-page: 126 year: 2000 ident: 2660_CR30 publication-title: Arthritis Res doi: 10.1186/ar77 – volume: 78 start-page: 57 year: 2001 ident: 2660_CR12 publication-title: Adv Immunol doi: 10.1016/S0065-2776(01)78002-9 – volume: 97 start-page: 451 year: 1994 ident: 2660_CR22 publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.1994.tb06109.x – volume: 168 start-page: 5333 year: 2002 ident: 2660_CR25 publication-title: J Immunol doi: 10.4049/jimmunol.168.10.5333 – volume: 148 start-page: 3296 year: 1992 ident: 2660_CR7 publication-title: J Immunol doi: 10.4049/jimmunol.148.10.3296 – volume: 44 start-page: 1 year: 2008 ident: 2660_CR13 publication-title: Cytokine doi: 10.1016/j.cyto.2008.06.017 – volume: 9 start-page: 224 year: 2007 ident: 2660_CR4 publication-title: Arthritis Res Ther doi: 10.1186/ar2333 – volume: 25 start-page: 361 year: 2005 ident: 2660_CR26 publication-title: Rheumatol Int doi: 10.1007/s00296-004-0449-x – volume: 9 start-page: 205 year: 2007 ident: 2660_CR6 publication-title: Arthritis Res Ther doi: 10.1186/ar2125 – volume: 170 start-page: 6320 year: 2003 ident: 2660_CR18 publication-title: J Immunol doi: 10.4049/jimmunol.170.12.6320 – volume: 166 start-page: 650 year: 2001 ident: 2660_CR29 publication-title: J Immunol doi: 10.4049/jimmunol.166.1.650 – volume: 40 start-page: 205 year: 2001 ident: 2660_CR1 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/40.2.205 – volume: 83 start-page: 579 year: 2003 ident: 2660_CR24 publication-title: Lab Invest doi: 10.1097/01.LAB.0000062854.30195.52 – volume: 52 start-page: 710 year: 2005 ident: 2660_CR14 publication-title: Arthritis Rheum doi: 10.1002/art.20932 – volume: 11 start-page: R84 year: 2009 ident: 2660_CR21 publication-title: Arthritis Res Ther doi: 10.1186/ar2718 – volume: 9 start-page: 219 year: 2007 ident: 2660_CR5 publication-title: Arthritis Res Ther doi: 10.1186/ar2200 – volume: 343 start-page: 1594 year: 2000 ident: 2660_CR33 publication-title: N Engl J Med doi: 10.1056/NEJM200011303432202 – volume: 172 start-page: 3422 year: 2004 ident: 2660_CR10 publication-title: J Immunol doi: 10.4049/jimmunol.172.6.3422 – volume: 95 start-page: 627 year: 2000 ident: 2660_CR19 publication-title: Blood doi: 10.1182/blood.V95.2.627 – volume: 31 start-page: 315 year: 1988 ident: 2660_CR16 publication-title: Arthritis Rheum doi: 10.1002/art.1780310302 – volume: 12 start-page: 1285 year: 2000 ident: 2660_CR17 publication-title: Int Immunol doi: 10.1093/intimm/12.9.1285 – volume: 164 start-page: 5010 year: 2000 ident: 2660_CR36 publication-title: J Immunol doi: 10.4049/jimmunol.164.10.5010 – volume: 165 start-page: 3423 year: 2000 ident: 2660_CR27 publication-title: J Immunol doi: 10.4049/jimmunol.165.6.3423 – volume: 93 start-page: 221 year: 1996 ident: 2660_CR32 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.1.221 – volume: 20 start-page: 929 year: 2006 ident: 2660_CR15 publication-title: Best Pract Res Clin Rheumatol doi: 10.1016/j.berh.2006.06.001 – volume: 173 start-page: 487 year: 1991 ident: 2660_CR8 publication-title: J Exp Med doi: 10.1084/jem.173.2.487 – reference: 15751074 - Arthritis Rheum. 2005 Mar;52(3):710-21 – reference: 16947627 - Arthritis Rheum. 2006 Sep;54(9):2793-806 – reference: 15004722 - Rheumatol Int. 2005 Jun;25(5):361-7 – reference: 11432208 - Adv Immunol. 2001;78:57-110 – reference: 7521808 - Clin Exp Immunol. 1994 Sep;97(3):451-7 – reference: 9930702 - Nature. 1999 Jan 21;397(6716):263-6 – reference: 1417131 - Ann Rheum Dis. 1992 Sep;51(9):1029-35 – reference: 16980215 - Best Pract Res Clin Rheumatol. 2006 Oct;20(5):929-39 – reference: 18177511 - Arthritis Res Ther. 2007;9(6):224 – reference: 1642656 - Arthritis Rheum. 1992 Aug;35(8):905-13 – reference: 11368435 - Leukemia. 2001 May;15(5):752-6 – reference: 11994492 - J Immunol. 2002 May 15;168(10):5333-41 – reference: 17850683 - Arthritis Res Ther. 2007;9(4):219 – reference: 10799853 - J Immunol. 2000 May 15;164(10):5010-4 – reference: 11257159 - Rheumatology (Oxford). 2001 Feb;40(2):205-11 – reference: 12088413 - Cell Immunol. 2001 Dec 15;214(2):145-54 – reference: 8552609 - Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):221-5 – reference: 16200580 - Arthritis Rheum. 2005 Oct;52(10):3004-14 – reference: 11094422 - Arthritis Res. 2000;2(2):126-31 – reference: 12794165 - J Immunol. 2003 Jun 15;170(12):6320-8 – reference: 18722135 - Cytokine. 2008 Oct;44(1):1-8 – reference: 10967023 - Int Immunol. 2000 Sep;12(9):1285-92 – reference: 17306038 - Arthritis Res Ther. 2007;9(1):202 – reference: 10975862 - J Immunol. 2000 Sep 15;165(6):3423-9 – reference: 1703209 - J Exp Med. 1991 Feb 1;173(2):487-9 – reference: 15004141 - J Immunol. 2004 Mar 15;172(6):3422-7 – reference: 19500335 - Arthritis Res Ther. 2009;11(3):R84 – reference: 17349064 - Arthritis Res Ther. 2007;9(2):205 – reference: 11123349 - J Immunol. 2001 Jan 1;166(1):650-5 – reference: 11086103 - J Immunol. 2000 Dec 1;165(11):6590-8 – reference: 12695561 - Lab Invest. 2003 Apr;83(4):579-88 – reference: 7545093 - Clin Exp Immunol. 1995 Sep;101(3):398-407 – reference: 10627472 - Blood. 2000 Jan 15;95(2):627-32 – reference: 11673556 - J Immunol. 2001 Nov 1;167(9):5381-5 – reference: 1578151 - J Immunol. 1992 May 15;148(10):3296-301 – reference: 11096166 - N Engl J Med. 2000 Nov 30;343(22):1594-602 – reference: 10714678 - Immunity. 2000 Feb;12(2):121-7 – reference: 3358796 - Arthritis Rheum. 1988 Mar;31(3):315-24 |
SSID | ssj0022924 |
Score | 2.2528431 |
Snippet | Introduction
Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to... Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the... Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to... INTRODUCTION: Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to... |
SourceID | pubmedcentral biomedcentral proquest gale pubmed crossref springer |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | R149 |
SubjectTerms | Antigens, CD - biosynthesis Arthritis, Rheumatoid - immunology Arthritis, Rheumatoid - metabolism B cells B-Cell Activation Factor Receptor - biosynthesis B-Lymphocytes - immunology B-Lymphocytes - metabolism Cell Proliferation Chemokine receptors Chemokines Chemotaxis, Leukocyte - immunology Development and progression Enzyme-Linked Immunosorbent Assay Flow Cytometry Genetic aspects Health aspects Humans Inducible T-Cell Co-Stimulator Ligand Lymphocyte Activation - immunology Medicine Medicine & Public Health Orthopedics Receptors, Chemokine - biosynthesis Receptors, Chemokine - immunology Research Article Rheumatoid arthritis Rheumatology Transmembrane Activator and CAML Interactor Protein - biosynthesis Tumor Necrosis Factor-alpha - biosynthesis |
Title | Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis |
URI | https://link.springer.com/article/10.1186/ar2823 https://www.ncbi.nlm.nih.gov/pubmed/19804625 https://www.proquest.com/docview/217489724 https://www.proquest.com/docview/21273606 https://www.proquest.com/docview/734157562 http://dx.doi.org/10.1186/ar2823 https://pubmed.ncbi.nlm.nih.gov/PMC2787286 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1La9wwEB6aFEovpekrbpqtDi09mdqyLMu9bZeEUEhPXcjNyLLcNQ122Af0F-R3Z0aWd2tDyc1GY1t4HvrmoRHAp1SnVZmVKkyzJAuF1lWoUy7CWNeqMtxGtQu4Xf-UV0vx4ya98fGOzVDtPqQknaV2aq3kV71G7yA5gqcp-uukgks-37tWHN0If3LQgXayh_12tPRMDfA_K9C0OnKSInUrz-VLeOEhI5v3PD6BJ7Z9Bc-ufVL8NdzTpv_uD14zNF_2Dr1oZv_6AteW6bZitHr1QT_mCzhYVzMzPId3LfvOKIi_-caaQ5E5a1qGCJHRucXdbzKLjXtyvbI7hLpdUzEUvZVrjPQGlpcXvxZXoT9eISwRM23DRIpYWVyPFKUmRWnQ1ERlpfPIylxp6mtvtUgya_JaaRGXxkQ2kzLiOql1kiVv4bjtWnsKzKBiV9KitTC5qJM6r2VcWgSHcalzNCEB8BEniru-lUZBza3HI8jyomdfAJ8HdhXGNyynczNuC-e4KLmn-7inG947pfhC3C5IZ_ENRvutBzh56n5VzNHvRdwqpAzgbBCIwivzpiCvTeUZF_il_ShqIXFFt7bbEQnCQPQFA2D_ocgQLiA0ljyAd718HSabK9oinAaQjSRv9JfGI22zcq3AOdpbruizg4wepj3-B-8fJzmD532ujAJMH-B4u97Zc4Rc23IGRwu5mLmAxcxp3gMDiTLn |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB7BVgIuVXmHAvUBxCkicRzH6W2pqJal2wut1JtlO043okqqfUj8An4348TZJZEQt0SeJFbm4W8eHgN8SFVa6EyLMM2SLGRKFaFKKQtjVYrCUBuVbcBtccln12x-k974eMe6r3bvU5KtpW7VWvDPaoXeQfIQDgQiEDaBg-l0_mO-c64oOhL-7KA99WgX-91g8Rmb4L_WoHF95ChJ2q4950dw6EEjmXZcfgoPbP0MHi18Wvw5_Hbb_pufeE3QgNl79KOJ_eVLXGui6oK49asL-xFfwkGakpj-ObyryRfiwvjrU1Lty8xJVRPEiMSdXNzcOsNYtU-ulnaLYLepCoLCt2xbI72A6_OvV2ez0B-wEGpETZsw4SwWFlck4ZKTTBs0NpEuVB5ZngvlOttbxZLMmrwUisXamMhmnEdUJaVKsuQlTOqmtq-BGFTtglu0FyZnZVLmJY-1RXgYa5WjEQmADjgh77tmGtK1tx6OINNlx74APvbsksa3LHcnZ9zJ1nURfEd3sqPr3zum-OS4LZ3W4huM8psPcPKu_5WcoueLyJVxHsBxLxDSq_NaOr9N5Bll-KXdKOqh44qqbbN1JAgE0RsMgPyDIkPAgOCY0wBedfK1n2wu3CbhNIBsIHmDvzQcqatl2wycosWlwn22l9H9tIf_4M3_SU7g8exqcSEvvl1-P4YnXebMhZvewmSz2tp3CMA2-r3XvT839TVY |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB5BkSouFW9CgfoA4hQ1D8dxuJW2q_JoxYFKvVmO47BRK2e1D4lfwO9mJnF2SSTELZEniZXxzHzjeRjgXaazqsxLGWZ5modc6yrUWcLDWNeyMomN6m7D7fJKXFzzLzfZjS8KWw3Z7kNIsq9poC5Nbn28qOpexKU41kv0FNL78ICTuaMQrTjdulkJuhT-FKEd7aSe_W5khqbK-C9rNM2UnIRLOys0ewQHHj6yk57fj-GedU9g_9IHyJ_Cb2oA0N7iNUNVZhfoUTP7yye7OqZdxciS9RuAzCdzsLZmZngO7xz7xGhDf_WRNbuEc9Y4hmiR0RnG7U9SkU335HJuNwh726ZiuAznXZOkZ3A9O_9xehH6oxbCEvHTOkwFj6VF2yQpTMlLg2onKitdRFYUUlOPe6t5mltT1FLzuDQmsrkQUaLTWqd5-hz2XOvsS2AGhbwSFjWHKXid1kUt4tIiUIxLXaA6CSAZcUIt-rYaihpdj0eQ_apnXwDvB3Yp45uX0xkad6pzYqTY0h1t6Yb3Tik-ELcVyS--wWhfhoCTp05Y6gR9YMSwXIgADocFobxgrxR5cLLIE45f2o6iRBJXtLPthkgQEqJfGAD7B0WO0AFhskgCeNGvr91kC0nlwlkA-Wjljf7SeMQ1864teIK6N5H02WGN7qY9_gev_k9yBPvfz2bq2-err4fwsA-h0b7Ta9hbLzf2DSKxdfm2E7w_heM4Lg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chemokine+receptor+expression+and+functional+effects+of+chemokines+on+B+cells%3A+implication+in+the+pathogenesis+of+rheumatoid+arthritis&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Nanki%2C+Toshihiro&rft.au=Takada%2C+Kazuki&rft.au=Komano%2C+Yukiko&rft.au=Morio%2C+Tomohiro&rft.date=2009-01-01&rft.pub=BioMed+Central+Ltd&rft.issn=1478-6354&rft.eissn=1478-6362&rft.volume=11&rft.issue=5&rft.spage=R149&rft.epage=R149&rft_id=info:doi/10.1186%2Far2823&rft.externalDBID=n%2Fa&rft.externalDocID=oai_biomedcentral_com_ar2823 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6354&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6354&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6354&client=summon |